tetano
Editor, Senior Moderator
J Neuroimmune Pharmacol
. 2021 Oct 16.
doi: 10.1007/s11481-021-10013-8. Online ahead of print.
Cannabis/Cannabinoids for Treating COVID-19 Associated Neuropsychiatric Complications
Jag H Khalsa[SUP] 1 2 3 [/SUP], Sanjay B Maggirwar[SUP] 4 [/SUP], Greg Bunt[SUP] 5 [/SUP]
Affiliations
Abstract
COVID-19 epidemic has resulted in devastating mortality and morbidity consisting of socioeconomic and health effects that have included respiratory/pulmonary, cardiovascular, mental health and neurological consequences such as anxiety, depression, and substance use. Several effective vaccines have been developed and extensive efforts are underway to develop therapeutics to treat COVID-19. Cannabis and/or its product-cannabidiol (CBD) are being advertised for the treatment of COVID-19 associated mental/neurological complications and substance use disorders. However, research reviewed shows that there is insufficient data from clinical studies to support the use of cannabis or CBD for the treatment of COVID-19 associated mental health and neurological complications. Additional basic and clinical research is suggested to develop cannabis or cannabidiol for the treatment of mental health problems associated with coronavirus infection and or substance use disorders. In the meantime, it is important that the addiction physician/psychiatrist must caution while prescribing or recommending cannabis or CBD for treating such clinical indications. Research shows that currently there is no clinical evidence to support the use of cannabis or any of its compounds including CBD for treating any of the neuropsychiatric complications of COVID-19. Thus, it is important that the addiction physicians/psychiatrists caution their patients from using cannabis or cannabis products for treating any such complications.
Keywords: CBD; COVID-19; Cannabidiol; Cannabis; Neuropsychiatric.
. 2021 Oct 16.
doi: 10.1007/s11481-021-10013-8. Online ahead of print.
Cannabis/Cannabinoids for Treating COVID-19 Associated Neuropsychiatric Complications
Jag H Khalsa[SUP] 1 2 3 [/SUP], Sanjay B Maggirwar[SUP] 4 [/SUP], Greg Bunt[SUP] 5 [/SUP]
Affiliations
- PMID: 34655372
- DOI: 10.1007/s11481-021-10013-8
Abstract
COVID-19 epidemic has resulted in devastating mortality and morbidity consisting of socioeconomic and health effects that have included respiratory/pulmonary, cardiovascular, mental health and neurological consequences such as anxiety, depression, and substance use. Several effective vaccines have been developed and extensive efforts are underway to develop therapeutics to treat COVID-19. Cannabis and/or its product-cannabidiol (CBD) are being advertised for the treatment of COVID-19 associated mental/neurological complications and substance use disorders. However, research reviewed shows that there is insufficient data from clinical studies to support the use of cannabis or CBD for the treatment of COVID-19 associated mental health and neurological complications. Additional basic and clinical research is suggested to develop cannabis or cannabidiol for the treatment of mental health problems associated with coronavirus infection and or substance use disorders. In the meantime, it is important that the addiction physician/psychiatrist must caution while prescribing or recommending cannabis or CBD for treating such clinical indications. Research shows that currently there is no clinical evidence to support the use of cannabis or any of its compounds including CBD for treating any of the neuropsychiatric complications of COVID-19. Thus, it is important that the addiction physicians/psychiatrists caution their patients from using cannabis or cannabis products for treating any such complications.
Keywords: CBD; COVID-19; Cannabidiol; Cannabis; Neuropsychiatric.